Profile data is unavailable for this security.
About the company
Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for patients and consumers. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Company operates through three segments: medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.
- Revenue in AUD (TTM)3.32m
- Net income in AUD-7.95m
- Incorporated2014
- Employees--
- LocationBod Science LtdLevel 1377 New South Head Road, Double BaySYDNEY 2028AustraliaAUS
- Phone+61 29199-5018
- Websitehttps://bodscience.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Holista Colltech Limited | 5.95m | -4.81m | 1.39m | 3.00 | -- | -- | -- | 0.2343 | -0.0172 | -0.0172 | 0.0213 | -0.0071 | 1.35 | 2.49 | 4.70 | -- | -111.49 | -42.59 | -347.69 | -63.58 | 56.66 | 56.37 | -82.68 | -39.27 | 0.2845 | -- | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
| Wellfully Ltd | 1.31m | -1.34m | 1.48m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
| Melodiol Global Health Ltd | 19.60m | -35.52m | 1.65m | -- | -- | -- | -- | 0.084 | -0.2548 | -0.3762 | 0.1578 | -0.0172 | 0.6874 | 4.35 | 10.62 | -- | -124.57 | -102.92 | -387.77 | -152.32 | 15.38 | -- | -181.22 | -348.92 | 0.1594 | -6.71 | 1.73 | -- | 210.13 | 94.60 | -62.47 | -- | -46.82 | -- |
| Hexima Ltd | 193.85k | -753.18k | 1.67m | -- | -- | 0.6564 | -- | 8.62 | -0.0045 | -0.0045 | 0.0012 | 0.0152 | 0.0558 | -- | 0.2705 | -- | -21.67 | -72.85 | -26.54 | -193.37 | -- | -- | -388.54 | -213.09 | -- | -- | 0.00 | -- | 271.52 | -19.43 | 80.85 | -- | -- | -- |
| Tryptamine Therapeutics Ltd | 1.21m | -4.32m | 1.93m | -- | -- | 1.78 | -- | 1.60 | -0.0162 | -0.0162 | 0.0037 | 0.0062 | 0.2368 | -- | -- | -- | -84.69 | -66.34 | -120.26 | -79.70 | -- | -- | -357.70 | -228.11 | -- | -21.62 | 0.00 | -- | -18.97 | 138.73 | 29.29 | -- | 68.45 | -- |
| Hydration Pharmaceuticals Co Ltd | 15.10m | -12.18m | 3.96m | -- | -- | -- | -- | 0.2626 | -0.0625 | -0.0625 | 0.0774 | -0.002 | 1.18 | 1.61 | 6.60 | -- | -94.86 | -79.98 | -143.75 | -111.57 | 53.70 | 48.73 | -80.69 | -99.53 | 1.37 | -21.48 | 1.10 | -- | 10.34 | 19.27 | 23.61 | -- | -- | -- |
| Bod Science Ltd | 3.32m | -7.95m | 4.26m | -- | -- | -- | -- | 1.28 | -0.0557 | -0.0557 | 0.0235 | -0.0046 | 0.7533 | 2.42 | 8.05 | -- | -180.40 | -94.62 | -465.66 | -145.77 | 69.23 | 47.08 | -239.47 | -129.48 | 0.8319 | -- | 3.71 | -- | -34.70 | 23.20 | -47.10 | -- | 8.23 | -- |
| Cambium Bio Ltd | -28.22k | -366.01k | 5.36m | -- | -- | -- | -- | -- | -0.0012 | -0.0012 | -0.00009 | -0.0036 | -0.039 | -- | -- | -- | -50.58 | -49.44 | -- | -292.47 | -- | -- | -- | -118.34 | -- | -- | -- | -- | -- | -- | 60.86 | -- | -- | -- |
| Zelira Therapeutics Ltd | 1.62m | -36.43m | 5.45m | 8.00 | -- | -- | -- | 3.36 | -3.23 | -3.23 | 0.148 | -0.2063 | 0.0848 | 0.185 | 3.55 | -- | -193.14 | -27.71 | -243.04 | -28.81 | 82.28 | -- | -2,278.17 | -508.48 | 0.1488 | -22.80 | -- | -- | -80.95 | -0.3635 | 53.35 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 3.94m | 761.17k | 6.22m | -- | 7.96 | 1.63 | 7.48 | 1.58 | 0.0054 | 0.0054 | 0.0273 | 0.0264 | 1.02 | -- | 76.13 | -- | 19.64 | -55.72 | 23.29 | -60.89 | -- | -- | 19.34 | -301.54 | -- | 54.64 | 0.00 | -- | 7,292.97 | 179.97 | 89.76 | -- | -- | -- |
| Invex Therapeutics Ltd | 837.95k | -6.01m | 6.31m | -- | -- | 1.19 | -- | 7.53 | -0.08 | -0.08 | 0.0112 | 0.0705 | 0.0521 | -- | 2.79 | -- | -37.38 | -- | -40.06 | -- | -- | -- | -717.76 | -- | -- | -- | 0.00 | -- | 379.22 | -- | -96.04 | -- | -- | -- |
